Abstract
The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field in order to standardize producers to assist the reasoning and decision-making of doctors. The information provided through this project must be assessed and criticized by the physician responsible for the conduct that will be adopted, depending on the conditions and the clinical status of each patient.
Highlights
The use of Daratumumab for treating amyloidosis is currently considered ‘off label’.Amyloidosis (AL), of light chain (LC) immunoglobulin, is a protein deposition disease characterized by different degrees of organic dysfunction, morbidity, and early death due to LC toxicity, usually produced by a population of clonal plasma cells
Sher T 20163 Report of 2 cases of AL, one with liver and heart failure and another with kidney failure, undergoing treatment with Daratumumab. Both patients showed a rapid decrease in free light chains (FLC) with adverse events that did not lead to the loss of adhesion
Report of 2 cases of severe AL, one with severe heart failure and another with heart and kidney failure, undergoing treatment with Daratumumab. Both patients showed a rapid decrease in free light chains (FLC) in response to infusions of Daratumumab, with few associated adverse events
Summary
Participants: Adriano Anzai[1] Armelin Utino[1] Haroldo Katayama[1] Ighor A. Z. Spir[1] Marcio A. Lemos[1] Mauricio Anhesini[1] Oswaldo S. N. Spir[1] Pericles Otani[1] Wanderley M. 1. Grupo de M.B. E – Presidente Prudente, Presidente Prudente, SP, Brasil 2. Coordenador do Programa Diretrizes da Associacao Medica Brasileira, Sao Paulo, SP, Brasil. The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field in order to standardize producers to assist the reasoning and decision-making of doctors. The information provided through this project must be assessed and criticized by the physician responsible for the conduct that will be adopted, depending on the conditions and the clinical status of each patient
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
